Access the Final Report: National Voluntary Consensus Standards for End Stage Renal Disease (ESRD) 2010: A Consensus Report
Measures focused only on chronic kidney disease will not be accepted for consideration in this project. NQF will consider measures that address chronic kidney disease as it relates to ESRD, such as effective transitioning to renal replacement therapy.
NOTE: All remaining NQF-endorsed® ESRD standards, as well as new renal measures, will be reviewed in an upcoming endorsement maintenance cycle project for renal disease.
The Opportunity
Over half a million American lives have been altered by a diagnosis of End Stage Renal Disease (ESRD), a serious condition that is almost always fatal unless treated with dialysis or transplantation. ESRD is the only disease-specific condition that is explicitly guaranteed Medicare coverage, with Medicare costs for the condition reaching $23.9 billion in 2007. In the same year, all-cause mortality rates for ESRD were roughly 6–8 times higher for dialysis patients than for the general population. 1
In 2007, incident rates of ESRD fell 2.1% to 354 per million population (over 527,000 cases) — the first decline in rates since 1995. Racial and ethnic differences persist, with 2007 rates in the African American and Native American populations 3.7 and 1.8 times greater, respectively, than the rate among Caucasians, and the rate in the Hispanic population 1.5 times higher than that of non-Hispanics. 2
In 2008, NQF endorsed 25 measures for ESRD care in the areas of anemia; dialysis adequacy; mineral metabolism; vascular access; influenza immunization; mortality; and patient education, perception of care, and quality of life. These measures were intended to facilitate efforts to improve the quality of care delivered to ESRD patients in all care settings, including dialysis facilities, in-home settings, physician offices, and hospitals.
The current project is limited to consideration of additional quality performance measures for patients with ESRD. However, measures that address chronic kidney disease (CKD) to a limited extent, such as those focused on transitioning to successful renal replacement therapy from stage 4 CKD or measures for which the evidence indicates applicability for both ESRD and CKD will be considered for endorsement.
The current project scope does not encompass comprehensive care for CKD which will be addressed in an upcoming endorsement maintenance cycle project for renal disease. Measure developers with renal measures outside the scope of this project (e.g. chronic kidney disease measures) may notify NQF via the “readiness to submit” form.
Although glycemic control and hypertension management may delay progression of kidney failure or cardiovascular complications, NQF-endorsed standards on those topics should be used for ESRD and CKD unless there is evidence supporting specific differences. Review of NQF-endorsed® standards relating to ESRD and/or CKD for maintenance of endorsement will only be conducted in this project if similar candidate standards are submitted that could potentially replace or expand the endorsed standard (e.g., relevant to pediatric patients in addition to adults). NOTE: All remaining NQF-endorsed® ESRD standards, as well as new renal measures, will be reviewed in an upcoming endorsement maintenance cycle project for renal disease.
About the Project
This project began in August 2010.
Objectives
NQF seeks to identify and endorse additional measures addressing quality of care for ESRD for public reporting and quality improvement. Measures also may address effective transitioning to renal replacement therapy. To the extent that the evidence indicates a measure focus also is applicable to CKD, it should be included in the target population (denominator). Measures focused only on CKD will not be accepted for consideration in this project.
NQF Process
Measures will be considered for NQF endorsement as national voluntary consensus standards. Consensus on the recommendations developed through NQF’s formal Consensus Development Process (CDP, Version 1.8). This project involves the active participation of representatives from across the spectrum of healthcare stakeholders and will be guided by a Steering Committee.
Funding
This project is supported under a contract provided by the Centers for Medicare & Medicaid Services.
Related NQF Work
National Voluntary Consensus Standards for End Stage Renal Disease Care: A Consensus Report
Contact Information
For further information, contact Katie Streeter at 202-783-1300 or via e-mail at esrd@qualityforum.org.
Notes
1. U.S. Renal Data System, USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2009.
Available at http://www.usrds.org/atlas.htm Last accessed on July 6, 2010.
2. Vassalotti, JA, Stevens, LA, Levey, AS, Testing for Chronic Kidney Disease: A Position Statement From the National Kidney Foundation, American Journal of Kidney Disease, 2007; 50(2):169-344, p.A1-A48.
This NQF project seeks to review and endorse new End Stage Renal Disease measures for quality improvement and public reporting.
NQF issued a Call for Intent to submit candidate standard for the ESRD project. Notices of intent closed on August 18, 2010.
The Call for Nominations for ESRD Steering Committee members closed on September 30, 2010. For more information, please refer to the Call for Nominations document.
Call for Nominations (PDF)
The 14-day review period for submitted nominees closed on December 3, 2010. The roster is to be finalized and will reflect input received during the roster review period and the expertise required for the Steering Committees scope of work.
The Call for Candidate Standards closed on September 30, 2010.
The Steering Committee began meeting in January 2011 to evaluate the submissions and prepare the draft report.
The Steering Committee met in person on January 11-12, 2011. The meeting was open to NQF Members and public.
-Measures Reviewed-
Anemia
1424: Monthly Hemoglobin Measurement for Pediatric Patients
1426: Assessment of Iron Stores
1428: Use of Iron Therapy When Indicated
1429: Avoidance of Iron Therapy in Iron Overload
1430: Lower Limit of Hemoglobin for Pediatric Patients
1431: Measurement of Iron Stores for Pediatric Patients
1433: Use of Iron Therapy for Pediatric Patients (REVISED)
Dialysis Adequacy
1418: Frequency of Adequacy Measurement for Pediatric Hemodialysis Patients
1421: Method of Adequacy Measurement for Pediatric Hemodialysis Patients (REVISED)
1423: Minimum spKt/V for Pediatric Hemodialysis Patients
Nutrition
1425: Measurement of nPCR for Pediatric Hemodialysis Patients (REVISED)
Fluid Weight Management
1432: Dietary Sodium Reduction Advice
1434: Sodium Profiling Practice for Hemodialysis
1435: Restriction of Dialysate Sodium
1437: Utilization of Dialysis Duration of Four Hours or Longer for Patients New to Dialysis
1438: Periodic Assessment of Post-Dialysis Weight by Nephrologists (REVISED)
1439: Utilization of High Ultrafiltration Rate for Fluid Removal
Infection
1449: Unavailable Blood Culture Results (percentage)
1450: Unavailable Clinical Confirmation (percentage)
1453: Clinically Confirmed Infection (rate)
1455: Access-related Bacteremia – using Medicare claims (rate) [stratified by access]
1456: Bacteremia (rate)
1457: Access-related Bacteremia (rate) [stratified by access]
1460: National Healthcare Safety Network (NHSN) Bloodstream Infection Measure (REVISED)
1469: Clinically Confirmed Access-related Infection (rate) [stratified by access]
1477: National Healthcare Safety Network (NHSN) Intravenous (IV) Antibiotic Start Measure
1478: National Healthcare Safety Network (NHSN) Vascular Access-Related Bloodstream Infection Measure
Mineral Metabolism
1427: Adult dialysis patients - serum phosphorus greater than 6 mg/dl
1454: Proportion of patients with hypercalcemia
1461: Proportion of patients with hypophosphatemia
Hospitalization
1463: Standardized Hospitalization Ratio for Admissions (REVISED)
1464: Standardized Hospitalization Ratio for Days
The Steering Committee met via conference call on February 11, 2011.
The draft report has been revised based on the comments received during the Public and Member Comment and consultation with the Steering Committee. Member voting closed on June 21, 2011.
CSAC met on July 13 and 14 to consider endorsement of 10 End Stage Renal Disease measures.
Agenda (PDF)
Review the CSAC meetings.
The public had 30 days to appeal the final decision made to endorse the 10 End Stage Renal Disease quality measures. The appeals period closed on September 14, 2011. No appeals were filed during this time.